Ultragenyx Pharmaceutical Inc.

NasdaqGS:RARE 株式レポート

時価総額：US$4.2b

Ultragenyx Pharmaceutical 将来の成長

Future 基準チェック /26

Ultragenyx Pharmaceutical利益と収益がそれぞれ年間54.2%と32%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-52.4% 54.5%なると予測されています。

主要情報

54.2%

収益成長率

54.5%

EPS成長率

Biotechs 収益成長28.4%
収益成長率32.0%
将来の株主資本利益率-52.4%
アナリストカバレッジ

Good

最終更新日21 Nov 2024

今後の成長に関する最新情報

Recent updates

Ultragenyx: Ready For More Growth After Q3 Earnings Beat

Nov 12

Ultragenyx: Excellent Company, Lackluster Stock

Nov 06

We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt

Sep 04
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt

Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective

Aug 22

There's Reason For Concern Over Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Massive 26% Price Jump

Aug 03
There's Reason For Concern Over Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Massive 26% Price Jump

Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being

Jun 12
Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being

Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching

Jun 06

We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt

May 24
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt

Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet

Mar 09

Will Ultragenyx Pharmaceutical (NASDAQ:RARE) Spend Its Cash Wisely?

Feb 01
Will Ultragenyx Pharmaceutical (NASDAQ:RARE) Spend Its Cash Wisely?

There's No Escaping Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Muted Revenues Despite A 28% Share Price Rise

Dec 28
There's No Escaping Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Muted Revenues Despite A 28% Share Price Rise

Is There An Opportunity With Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 47% Undervaluation?

Sep 12
Is There An Opportunity With Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 47% Undervaluation?

An Intrinsic Calculation For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Suggests It's 50% Undervalued

May 24
An Intrinsic Calculation For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Suggests It's 50% Undervalued

Improved Revenues Required Before Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Find Their Feet

Apr 17
Improved Revenues Required Before Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Find Their Feet

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 33% Below Their Intrinsic Value Estimate

Feb 18
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 33% Below Their Intrinsic Value Estimate

業績と収益の成長予測

NasdaqGS:RARE - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/2026878-344-160-30817
12/31/2025636-502-233-32320
12/31/2024542-564-412-39520
9/30/2024523-559-440-419N/A
6/30/2024481-585-492-469N/A
3/31/2024443-613-544-509N/A
12/31/2023434-607-522-475N/A
9/30/2023410-635-553-481N/A
6/30/2023403-721-553-459N/A
3/31/2023384-719-529-420N/A
12/31/2022363-707-527-380N/A
9/30/2022343-678-480-344N/A
6/30/2022334-506-438-309N/A
3/31/2022332-470-416-297N/A
12/31/2021351-454-412-339N/A
9/30/2021360-356-426-347N/A
6/30/2021359-351-411-349N/A
3/31/2021334-204-243-196N/A
12/31/2020271-187-176-132N/A
9/30/2020215-256-175-142N/A
6/30/2020159-301-203-168N/A
3/31/2020122-425-381-345N/A
12/31/2019104-403-370-345N/A
9/30/201984-397-344-329N/A
6/30/201970-371-320-310N/A
3/31/201959-325-304-297N/A
12/31/201851-198-295-291N/A
9/30/201838-192-320-317N/A
6/30/201826-183N/A-309N/A
3/31/201813-204N/A-282N/A
12/31/20173-302N/A-254N/A
9/30/20170-292N/A-220N/A
6/30/20170-277N/A-186N/A
3/31/20170-261N/A-177N/A
12/31/20160-246N/A-161N/A
9/30/20160-230N/A-154N/A
6/30/20160-204N/A-156N/A
3/31/2016N/A-177N/A-133N/A
12/31/2015N/A-146N/A-106N/A
9/30/2015N/A-107N/A-78N/A
6/30/2015N/A-84N/A-58N/A
3/31/2015N/A-68N/A-52N/A
12/31/2014N/A-65N/A-45N/A
9/30/2014N/A-67N/A-42N/A
6/30/2014N/A-63N/A-38N/A
3/31/2014N/A-61N/A-36N/A

アナリストによる今後の成長予測

収入対貯蓄率: RARE今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: RARE今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: RARE今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: RAREの収益 ( 32% ) US市場 ( 9% ) よりも速いペースで成長すると予測されています。

高い収益成長: RAREの収益 ( 32% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: RARE 3 年以内に赤字になると予測されています。

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y